|
CN104278037B
(zh)
|
2005-10-12 |
2020-09-15 |
艾德拉药物股份有限公司 |
基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
|
|
AU2008229483A1
(en)
*
|
2007-03-16 |
2008-09-25 |
University Of Florida Research Foundation, Inc. |
Kinase protein binding inhibitors
|
|
MX2011003625A
(es)
*
|
2008-10-06 |
2011-05-31 |
Idera Pharmaceuticals Inc |
Uso de inhibidores de receptores tipo toll en la prevencion y tratamiento de hipercolesterolemia e hiperlipidemia y enfermedades relacionadas con esto.
|
|
AU2009323766B2
(en)
|
2008-12-02 |
2016-10-06 |
Wave Life Sciences Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
CA2750499A1
(en)
*
|
2009-01-30 |
2010-08-05 |
Idera Pharmaceuticals, Inc. |
Novel synthetic agonists of tlr9
|
|
BRPI1009842B8
(pt)
|
2009-03-25 |
2021-05-25 |
Univ Texas |
uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
|
|
SG177564A1
(en)
|
2009-07-06 |
2012-02-28 |
Ontorii Inc |
Novel nucleic acid prodrugs and methods of use thereof
|
|
EP2451974A2
(en)
*
|
2009-07-08 |
2012-05-16 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
|
US20110015219A1
(en)
*
|
2009-07-16 |
2011-01-20 |
Mallinckrodt Inc. |
(+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
|
|
US10363251B2
(en)
|
2009-07-16 |
2019-07-30 |
Mallinckrodt Llc |
(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
|
|
ES2538347T3
(es)
*
|
2009-08-27 |
2015-06-19 |
Idera Pharmaceuticals, Inc. |
Composiciones para inhibir expresión genética y usos de las mismas
|
|
WO2011041311A2
(en)
*
|
2009-09-29 |
2011-04-07 |
Yale University |
Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
|
|
JP2011084517A
(ja)
*
|
2009-10-15 |
2011-04-28 |
Koreaki Taniguchi |
核酸により活性化される自然免疫応答の抑制剤及びスクリーニング方法
|
|
US20130079505A1
(en)
*
|
2010-03-24 |
2013-03-28 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
|
PL2593095T3
(pl)
|
2010-07-16 |
2019-12-31 |
Mallinckrodt Llc |
(+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
|
|
GB201014026D0
(en)
*
|
2010-08-20 |
2010-10-06 |
Ucl Business Plc |
Treatment
|
|
US9186371B2
(en)
|
2010-09-17 |
2015-11-17 |
Japan Science And Technology Agency |
Inhibitor of HMGB protein-mediated immune response activation, and screening method
|
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
|
EP2640420B1
(en)
|
2010-11-19 |
2018-08-15 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
GB201022049D0
(en)
*
|
2010-12-29 |
2011-02-02 |
Imp Innovations Ltd |
Methods
|
|
US8877722B2
(en)
*
|
2011-03-25 |
2014-11-04 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
|
CN103687606B
(zh)
*
|
2011-05-16 |
2018-08-17 |
豪斯生物药业公司 |
特定草药制剂的治疗性组合物及其用途
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
JP6246121B2
(ja)
*
|
2012-07-13 |
2017-12-13 |
株式会社新日本科学 |
キラル核酸アジュバント
|
|
JP6268157B2
(ja)
|
2012-07-13 |
2018-01-24 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
不斉補助基
|
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
CN103845731B
(zh)
*
|
2012-12-05 |
2015-12-02 |
复旦大学 |
抗st2/il-1r4抗体在制备防治瘙痒药物中的应用
|
|
CN103845730B
(zh)
*
|
2012-12-05 |
2015-12-09 |
复旦大学 |
抗st2/il-1 r4抗体在制备镇痛药物中的用途
|
|
CA2896537C
(en)
*
|
2013-01-08 |
2021-10-12 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
RU2014102941A
(ru)
*
|
2013-02-05 |
2015-08-10 |
Нитто Денко Корпорейшн |
Вакцинная композиция для введения через слизистую оболочку
|
|
GB2514591A
(en)
|
2013-05-30 |
2014-12-03 |
Mologen Ag |
Predictive biomarker for cancer therapy
|
|
EP3095460A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
PT3094728T
(pt)
|
2014-01-16 |
2022-05-19 |
Wave Life Sciences Ltd |
Desenho quiral
|
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
US10286065B2
(en)
|
2014-09-19 |
2019-05-14 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
|
AU2015349680A1
(en)
|
2014-11-21 |
2017-06-08 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
|
SK500652015A3
(sk)
|
2015-10-15 |
2017-05-03 |
Ústav Polymérov Sav |
Spôsob úpravy funkčného stavu ľubovoľnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie
|
|
CN105597079A
(zh)
*
|
2016-01-11 |
2016-05-25 |
中国人民解放军第三军医大学第一附属医院 |
用于治疗银屑病的药物
|
|
CN105541947A
(zh)
*
|
2016-01-11 |
2016-05-04 |
中国人民解放军第三军医大学第一附属医院 |
拮抗tlr7/8及tlr9活化的药物分子及用途
|
|
JP7034951B2
(ja)
|
2016-06-08 |
2022-03-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
操作されたウイルスベクターは炎症および免疫応答の誘導を低減する
|
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
|
WO2018089695A1
(en)
|
2016-11-11 |
2018-05-17 |
Dynavax Technologies Corporation |
Toll-like receptor antagonist compounds and methods of use
|
|
CA3044484A1
(en)
|
2016-11-23 |
2018-05-31 |
Berlin Cures GmbH |
Aptamers for use in inhibition and/or suppression of tlr9 activation
|
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
|
WO2019020732A1
(en)
|
2017-07-27 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS FOR DETERMINING WHETHER A PATIENT SUFFERING FROM RHABDOMYOLYSIS REACHES A RESPONSE WITH AN ANTAGONIST TLR9
|
|
WO2019094548A1
(en)
|
2017-11-08 |
2019-05-16 |
President And Fellows Of Harvard College |
Compositions and methods for inhibiting viral vector-induced inflammatory responses
|
|
WO2019226977A1
(en)
*
|
2018-05-25 |
2019-11-28 |
Primmune Therapeutics, Inc. |
Tlr7 agonists
|
|
PE20221324A1
(es)
|
2019-11-26 |
2022-09-09 |
Primmune Therapeutics Inc |
Agonistas del tlr7
|
|
AU2021206355A1
(en)
*
|
2020-01-10 |
2022-07-07 |
Sbi Biotech Co., Ltd. |
Novel TLR9 agonists
|